Santa Fe Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Santa Fe Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-65,515	Closed	-$3.7M	–	569
2015 Q3	$3.7M	Buy	65,515 +6,336	+11%	+$411K	0.49%	41
2015 Q2	$3.5M	Buy	59,179 +12,512	+27%	+$772K	0.48%	50
2015 Q1	$2.91M	Buy	+46,667	New	+$2.71M	0.35%	88
2014 Q3	–	Sell	-46,737	Closed	-$2.45M	–	593
2014 Q2	$2.45M	Buy	+46,737	New	+$2.39M	0.37%	90

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Santa Fe Partners's TEVA Position: Q4 2015 in Review

Santa Fe Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 65,515 shares — an estimated $3.7M sold.

Santa Fe Partners first reported a position in TEVA in Q2 2014 and held it in 4 quarters. The position peaked at $3.7M in Q3 2015. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

Santa Fe Partners reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Santa Fe Partners sold 65,515 Teva Pharmaceuticals shares in Q4 2015, an estimated $3.7M.
Santa Fe Partners first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 4 quarters.
Santa Fe Partners's Teva Pharmaceuticals position peaked at $3.7M in Q3 2015.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on Santa Fe Partners's 13F filing for Q4 2015, filed 12 Feb 2016.